Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the established first-line care against advanced NSCLC carrying sensitizing EGFR mutations, and have a considerable higher efficacy than the standard chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.